[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"efficacy-self\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:efficacy-self":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,45,70,117,145,168,195,226,255,278,304,330,353],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100451881","phase-4-real-world-safety--efficacy-experience-of-empagliflozin-with-or-without-metformin-in-t2dm-patients---ease-study-100451881",false,"NCT05164263","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study","Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus","EASE","Inclusion Criteria:\n\nPatient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL\u002Fmin\u002F1.73m2.\n\nExclusion Criteria:\n\nType 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and\u002For hepatic dysfunctions, where RFT and Urine R\u002FE is abnormal, Diabetic Ketoacidosis and\u002For hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},2000,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.\n\nStudy design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.\n\nSample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).\n\nFollow up visits: After recruitment, patient is supposed to have three visits for follow-ups.\n\nVisit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.\n\nLABORATORY TESTING:\n\nReputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R\u002FE. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.\n\nWhere in Urine Routine Examination (Urine R\u002FE), we consider as follows:\n\n* Visual Examination:\n\n  * Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.\n  * Urine clarity: Clear, slightly Cloudy, cloudy or turbidity\n* Chemical Examination:\n\n  * Specific gravity\n  * pH\n  * Bilirubin\n  * Urobilinogen\n  * Protein\n  * Ketone\n  * Leukocyte Esterase\n* Microscopic Examination:\n\n  * Red Blood Cells:\n  * Epithelial Cells:\n  * Amorphous:\n  * Pus Cells\n  * Bacteria\n  * Yeast\n  * Casts\n  * Crystals\n\nWhere in Renal Function Test (RFT), we consider as follows:\n\n* Blood Urea Nitrogen (BUN): mg\u002FdL\n* Serum Creatinine: mg\u002FdL\n* Estimated Glomerular Filtration Rate (eGFR): mL\u002Fmin\u002F1.73 m2",[29,30,31],"Type II Diabetes Mellitus","Efficacy, Self","Safety Issues","RECRUITING","2026-01-20",{"date":35,"type":36},"2026-01-22","ACTUAL",{"date":38,"type":36},"2021-04-01",{"date":40,"type":23},"2027-08-31",{"name":42,"class":43},"Getz Pharma","INDUSTRY",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100428626","the-safety-and-efficiency-of-endovascular-treatment-of-acute-or-subacute-thromboembolic-occlusions-of-lower-extremity-100428626","NCT04861506","The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Physician-initiated, Prospective, Multi-center, Observational Study: The Safety and Efficiency Result of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Inclusion criteria\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute or subacute limb ischemia classified as Rutherford classification stage I to IIb.\n3. Rutherford classification ranging from 3 to 5.\n4. Successful guidewire passage through the lesion of the femoropopliteal artery lesion, followed by further endovascular treatment. There are no restrictions will be implemented on the methods used for guidewire passage through the target lesion. The presence of thrombus must be confirmed via angiography and\u002For DSA and must be associated with occlusions of the lower extremity or ISR.\n5. Mechanical thrombectomy device (MTD) and\u002For pharmacomechanical thrombectomy (PMT) and\u002For percutaneous aspiration thrombectomy(PAT) and\u002For CDT (catheter-directed thrombolysis) performed for thrombus removal.\n6. The lower extremity artery must have a healthy runoff of at least 10 cm above the ankle with at least one healthy dorsalis pedis artery, medial plantar artery, or lateral plantar artery connecting to the digital artery below the ankle.\n7. Informed consent signed by patients.\n\nExclusion criteria\n\n1. Acute or subacute limb ischemia patients with Rutherford classification stage III.\n2. Patients diagnosed with thromboangiitis obliterans.\n3. Patients requring open surgery or hybrid operation after contrast radiography.\n4. Patients with a history of stroke, cerebral hemorrhage, gastrointestinal bleeding, myocardial infarction, or similar conditions in the past 3 months.\n5. Patients with known allergies to heparin, low molecular weight heparin, or contrast agents.\n6. Patients at high risk for bleeding.\n7. Pregnant or lactating women.\n8. Patients with other conditions that may complicate study participation or significantly reduce life expectancy (\\\u003C 2 years), such as tumors, severe liver disease, and cardiac insufficiency.\n9. Patients enrolled in other clinical studies within the past 3 months.\n10. Patients unwilling or refusing to sign the informed consent form.\n\n    \\-",{"count":53,"type":23},400,"OBSERVATIONAL","Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.",[57,58,59,31,30],"Thromboembolic Disease","Lower Extremity Problem","Endovascular Treatment","2025-09-12",{"date":62,"type":36},"2025-09-15",{"date":38,"type":36},{"date":65,"type":23},"2025-12-31",{"name":67,"class":68},"First People's Hospital of Hangzhou","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":18,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":69},"100537743","neuromodulation-of-the-autonomic-nervous-system-in-athletes-100537743","NCT06281795","Neuromodulation of the Autonomic Nervous System in Athletes","Neuromodulation of the Autonomic Nervous System in Athletes (NANSA Trial)","NANSA","Inclusion Criteria:\n\n* Professional athletes over the age of 15 and under the age of 35;\n* Cyclic sports (swimming, modern pentathlon, athletics, triathlon);\n* Difficult coordination sports (dance sports, rhythmic gymnastics);\n* Sports category: no lower than candidate for master of sports;\n* Voluntary informed consent.\n\nExclusion Criteria:\n\n* Atypical and unrelated to physical exertion changes on the ECG (T wave inversion, st-segment depression, pathological Q waves, signs of left atrial enlargement, signs of right ventricular hypertrophy, ventricular pre-excitation, complete right or left bundle branch block, prolonged or shortened Q-T interval, Brugada-like early repolarization);\n* Heart rhythm and conduction disorders (frequent ventricular and supraventricular extrasystoles, first-degree atrioventricular block (P-Q \\> 0.21 s, not shortened during hyperventilation or physical exertion), second or third degree);\n* Expressed sinus bradycardia with resting heart rate \\\u003C 40 bpm;\n* Taking glucocorticosteroids in the last 1 month;\n* Taking any antiarrhythmic drugs, including beta-blockers.","15 Years","35 Years",{"count":81,"type":23},125,[83],"NA","There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion). It has been demonstrated that tVNS in athletes improved the rate of heart rate recovery, reduced lactic acid levels in blood plasma, reduced pain, reduced overtraining syndrome and fatigue levels.",[30,86,87,88],"Fatigue; Muscle, Heart","Fatigue, Mental","Fatigue; Combat",[90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106],"auricular stimulation","auricular vagus nerve stimulation","transcutaneous vagus nerve stimulation (tVNS)","vagus nerve stimulation (VNS)","heart rate","heart rate variability","power of high-frequency oscillations (HF)","power of low-frequency oscillations (LF)","LF\u002FHF","index centralization (IC)","index of vegetative balance (IVB)","athletes","sport","maximum oxygen consumption (VO2max)","treadmill speed","anaerobic threshold of metabolism.","aerobic metabolism threshold of metabolism","2025-06-23",{"date":109,"type":36},"2025-06-26",{"date":111,"type":36},"2024-04-01",{"date":113,"type":23},"2026-01-31",{"name":115,"class":116},"Bakulev Scientific Center of Cardiovascular Surgery","OTHER_GOV",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":69},"100592002","comparing-different-diameter-furss-with-similar-resds-for-the-treatment-of-upper-urinary-tract-stones-100592002","NCT06987760","Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones","Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones - A Randomized Controlled Multi-center Clinical Trials","Inclusion Criteria:\n\n\\- 1.Patients with kidney stones or upper ureteral stones with a cumulative diameter of less than 3 cm are selected for ureteral soft lens holmium laser lithotripsy.\n\n2.Age 18 to 80 years old, gender unlimited. 3.The subjects have no mental illness or language dysfunction, can understand the situation of the study and can sign informed consent.\n\nExclusion Criteria:\n\n* 1.Patients with a history of ureteral stenosis or who have undergone open or laparoscopic ureteral or renal lithotomy.\n\n  2.Patients with fever one week before surgery 3.Pregnant women and menstruating patients. 4.Patients with combined systemic disease or inability to tolerate anesthesia. 5.Patients undergoing simultaneous surgery for bilateral upper urinary tract stones.\n\n  6.Patients with ureteral stent indwelling before surgery. 7.In patients with severe hydronephrosis, the separation of the renal collecting system is greater than 4 cm.\n\n  8.Patients with renal anatomic malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney.","80 Years",{"count":126,"type":23},206,[83],"Comparing the Efficiency, Effectiveness, and Safety of fURS lithotripsy with Similar RESDs in the Treatment of Upper Urinary Tract Stones.",[130,131,30],"Ureter Injury","Urolithiasis; Lower Urinary Tract",[133,134,135],"Urolithiasis","Ratio of Endoscope-Sheath Diameter","Flexible ureteroscope","2025-05-22",{"date":138,"type":36},"2025-05-23",{"date":140,"type":36},"2025-03-19",{"date":142,"type":23},"2026-12-30",{"name":144,"class":68},"Ningbo No. 1 Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":18,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":69},"100484051","tenofovir-alafenamide-switch-therapy-in-chronic-hepatitis-b-100484051","NCT05583006","Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B","A Prospective Cohort Study of Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B Patients Who Are Unsatisfied to Entecavir Therapy","Inclusion Criteria:\n\n1. At least 20 years of age\n2. Detectable serum HBsAg\n3. Chronic HBV infection under ETV therapy\n4. ETV users who are unsatisfied with the efficacy and\u002For feel inconvenient of ETV therapy\n5. No contraindications for TAF switch therapy\n6. HBV antiviral period expectancy for at least 1 year\n\nExclusion Criteria:\n\n1. End stage renal disease (estimated glomerular filtration rate \\[eGRF\\]\\\u003C 15 mL\u002Fmin\u002F1.73m2) without dialysis\n2. Co-infected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus\n3. Any active malignancies\n4. Under immunosuppressants\n5. Known allergy to tenofovir-contained regimens","20 Years",{"count":154,"type":23},60,"Chronic hepatitis B (CHB) patients may be unsatisfied to entecavir (ETV) therapy due to the inconvenience in drug taking, i.e., fasting for more than 2 hours and\u002For dose adjustment according to estimated glomerular filtration rate (eGFR). However, tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with CHB, and is convenient in drug taking, i.e., once daily regardless food taking and renal function.Therefore,TAF can be a good option in CHB patients who are unsatisfied to ETV therapy. The aim of this prospective cohort study is to assess the improvement on satisfaction (including drug adherence) of TAF switch therapy in CHB patients who are unsatisfied to ETV therapy. In addition, with expected adherence improvement in TAF switch therapy, the efficacy of TAF switch therapy may be improved, and the efficacy benefits can be evaluated by the changes of some novel biomarkers, such as HBV core-related antigen (HBcrAg). The investigators therefore aim to conduct a prospective cohort study of TAF switch therapy for CHB patients who are unsatisfied to ETV therapy.",[157,158,30,31],"Patient Satisfaction","Drug Adherence","2025-01-07",{"date":161,"type":36},"2025-01-09",{"date":163,"type":36},"2023-11-06",{"date":165,"type":23},"2028-12-30",{"name":167,"class":68},"Taichung Veterans General Hospital",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":17,"sex":18,"minAge":152,"maxAge":20,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100571572","comparing-of-using-interactive-e-books-and-traditional-education-methods-for-nursing-students-and-nursing-staff-100571572","NCT06722001","Comparing of Using Interactive E-books and Traditional Education Methods for Nursing Students and Nursing Staff","Comparing the Effectiveness of Brief Behavioral Treatment of Insomnia(BBTI) for Nursing Students and Nursing Staff Using Interactive E-books and Traditional Education Methods - a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Nursing students older than 20 years old.\n2. Clinical nurses worked in the hospital more than three months.\n\nExclusion Criteria:\n\n1. cognitive disabilities\n2. incomplete behavioral ability",{"count":176,"type":23},180,[83],"Cancer-related comorbidities are a major focus of care for medical staff, especially the incidence of \"insomnia\" in cancer patients should not be underestimated, and the treatment of cancer-related insomnia by clinical medical staff is often limited to verbal instructions and suggestions, lacking routine and a systematic process. Although \"Cognitive behavioral treatment for insomnia (CBTI)\" is widely used, due to the limitation of personnel and high time cost, later generations improved \"Brief Behavioral Treatment of Insomnia (BBTI)\", which not only broadens the clinical application but also increases the patient's willingness to cooperate.\n\nIn recent years, the integration of technology into teaching has become a trend. Among them, interactive e-books are widely used. It not only enhances users' learning motivation and interest but also is effective in building practical confidence. It can also customize course content according to different needs.\n\nThe purpose of this study is to compare the effectiveness of using interactive e-book teaching and traditional teaching methods to learn Brief Behavioral Treatment of Insomnia. The object is aimed at nursing students and clinical nurses. An experimental research design is adopted. A total of 165\\~180 clinical nurses and university nursing students will be pre-selected and randomly assigned to the control group or the experimental group. The control group learned through paper health education leaflets and traditional oral explanations; the experimental group used interactive e-books to intervene in learning Brief Behavioral Treatment of Insomnia, the subjects needed to fill out the pre-test and post-test questionnaires before and after the experiment to compare the difference in the learning effects of the two groups of subjects, and expect that the group using interactive e-book will have better learning effects and course satisfaction.",[30,180],"Satisfaction, Personal",[182,183,184],"Brief Behavioral Treatment of Insomnia","e-book","Insomnia treatment","NOT_YET_RECRUITING","2024-12-03",{"date":188,"type":36},"2024-12-09",{"date":190,"type":23},"2024-12-30",{"date":192,"type":23},"2025-02-28",{"name":194,"class":68},"Taipei Medical University",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":18,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":206,"studyType":54,"phases":4,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":69},"100550415","pipeline-embolization-for-intracranial-aneurysms-100550415","NCT06446778","Pipeline Embolization for Intracranial Aneurysms","Pipeline Embolization Device for Intracranial Aneurysm (PEDIA): a Prospective, Multicenter Cohort Focus on Safety, Efficacy, and Haemodynamics","Inclusion criteria:\n\n1. Aged 22 to 75 years old, male or non-pregnant female;\n2. UIA was diagnosed by CTA, MRA, or DSA;\n3. The size of aneurysms is between 3 to 25mm;\n4. Understands the nature of the procedure and provision of written informed consent;\n5. Indications for FD implantation with or without adjunctive coiling;\n6. Is willing to return to the investigational site for follow-up according to our protocol.\n\nExclusion criteria:\n\n1. With contraindications to flow-diversion treatment or known allergy to cobalt-chromium alloy or contrast medium;\n2. Pregnancy or lactation;\n3. Coexist with other vascular lesions (coronary artery disease, abdominal aortic aneurysm, severe intracranial artery stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.);\n4. Parent vessel with a diameter \\\u003C2.0 mm or ≥5.0 mm.;\n5. Unwilling to be followed up or likely to have poor treatment compliance;\n6. Life expectancy less than 3 years;\n7. Inability to receive anti-platelet or anticoagulant medication;\n8. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4);\n9. Enrollment in another trial or other situations that the researcher deems unsuitable for inclusion in the study.","22 Years","75 Years",{"count":205,"type":23},1000,"3 Years","This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.",[30,209,210,211],"Hemodynamic Instability","Stenosis","Aneurysm, Intracranial",[213,214,215,216],"intracranial aneurysms","flow-diverter device","Pipeline embolization device","in-stent stenosis","2024-11-13",{"date":219,"type":36},"2024-11-18",{"date":221,"type":36},"2022-09-01",{"date":223,"type":23},"2030-09-01",{"name":225,"class":68},"Zhujiang Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":234,"targetDuration":236,"studyType":54,"phases":4,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100550751","lower-silesian-orbital-atherectomy-registry-loar-100550751","NCT06451146","Lower Silesian Orbital Atherectomy Registry (LOAR)","Evaluation of the Safety and Efficacy of Orbital Atherectomy (OA) for Calcified Lesions in Patients With Coronary Artery Disease: The Lower Silesian Orbital Atherectomy Registry (LOAR)","LOAR","Inclusion Criteria:\n\n* The presence of moderately to severely calcified lesions.\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Target vessel perforation due to previous unsuccessful lesion preparation\n* Pregnancy",{"count":235,"type":23},500,"5 Years","The Lower Silesian Orbital Atherectomy Registry (LOAR), is an observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of the Orbital Atherectomy Device due to the presence of calcified lesion in coronary arteries. Data will be collected in two cooperating cardiac centers (Department of Cardiology, The Copper Health Center, Lubin, Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).",[31,30],[240,241,242,243,244],"Percutaneous coronary interventions","Calcified Lesion","Coronary artery diseases","Orbital Atherectomy","Lesion preparation","2024-08-19",{"date":247,"type":36},"2024-08-21",{"date":249,"type":36},"2022-05-01",{"date":251,"type":23},"2027-05-01",{"name":253,"class":68},"Regional Cardiology Center, The Copper Health Centre (MCZ),",2,{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":203,"enrollmentInfo":262,"targetDuration":4,"studyType":24,"phases":264,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":185,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":69},"100553843","phase-2-first-line-treatment-induced-with-mfolfox6-and-hlx04-regimen-following-combined-with-serplulimab-in-mss-initially-unresectable-metastatic-colorectal-cancer-100553843","NCT06491355","First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer","Efficacy and Safety of First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer: A Prospective, Multicenter, Randomized, Controlled Trial (ASTRUM-IUmCRC)","Inclusion Criteria:\n\n1. The patient volunteered to participate in the study, signed the informed consent form, and had good compliance.\n2. Age: 18-75 years old (including 18 years old and 75 years old).\n3. Body weight of 40kg.\n4. Metastatic colorectal cancer confirmed by histology and \u002F or cytology and initially unresectable.\n5. MSS type or pMMR.\n6. Patients are required to have at least one measurable lesion (RECIST 1.1).\n7. ECOG physical strength status: 0-1 point.\n8. Expected survival of 12 weeks.\n9. Blood test (no transfusion within 14 days, no correction with granulocyte colony stimulating factor or other hematopoietic stimulating factor within 7 days before the laboratory test)\n\n   1. Absolute neutrophil value of 1.5109\u002F L, platelet 1010109\u002F L, hemoglobin concentration of 9 g\u002FdL);\n   2. Liver function test (bilirubin 1.5 ULN; aspartate aminase and glutamate aminase 2.5 ULN, AST and ALT 5 ULN);\n   3. Renal function (serum creatinine 1.5 ULN or creatinine clearance (CCr) 60 mL\u002Fmin);\n   4. Coagulation (international normalized ratio (INR) 1.5 ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) 1.5 ULN);\n   5. Thyroid function, upper limit of normal (TSH); if abnormal, FT3 and FT4 levels should be examined, normal FT3 and FT4 levels can be included.\n10. Women of childbearing age must have a negative serum pregnancy test within 14 days before treatment and be willing to use medically approved effective contraception (e. g., IU, contraceptives or condoms) during 3 months after the study and the last study drug; surgical sterilization for male subjects with a woman of childbearing age, or effective contraception is recommended during the study and 3 months after the last study dose.\n\nExclusion Criteria:\n\n1. Have received the following treatments within the first 4 weeks of treatment: tumor radiotherapy, surgery, chemotherapy, immune or molecular targeted therapy, and other clinical study drugs.\n2. Active autoimmune diseases requiring systemic treatment (i. e., corticosteroids or immunosuppressive agents) have occurred in the past 2 years. Alternative therapies (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment.\n3. Diagnosis with immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first treatment. A physiological dose of corticosteroids may be approved after consultation with the investigator.\n4. Previous small molecule targeted drug therapy, such as fuquintinib, etc.\n5. Previous treatment with an oxaliplatin-based chemotherapy regimen.\n6. Symptomatic brain or meningeal metastases.\n7. Metastatic colorectal cancer with either MSI-H or dMMR.\n8. Severe infection (e. g. intravenous infusion of antibiotics, antifungals or antiviral drugs), or unexplained fever\\> 38.5℃ during screening \u002F first dose.\n9. Hypertension that is not well controlled with antihypertensive medication (systolic 140 mmHg or diastolic 90 mmHg).\n10. Significant clinical bleeding symptoms or significant bleeding tendency (bleeding\\> 30 mL, hematemesis, black feces, stool within 3 months), hemoptysis (\\> 5 mL of fresh blood within 4 weeks); or venous \u002F venous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; or long-term anticoagulation with Chinese standard or heparin, or long-term antiplatelet therapy (aspirin 300 mg \u002F day or clopidogrel 75 mg \u002F day).\n11. During screening, the tumor was found to invade large vascular structures, such as pulmonary artery, superior vena cava vein or inferior vena cava vein, which was judged to be at risk of large bleeding by the investigators.\n12. Active heart disease, including myocardial infarction, severe \u002F unstable angina, within 6 months before treatment. Echocardiography showed a left ventricular ejection fraction of \\\u003C50%, and the arrhythmia was poorly controlled.\n13. Other malignancies within or during the previous 5 years (except for cured skin basal cell carcinoma and carcinoma of the cervix in situ).\n14. Known allergy to the study drug or any of its excipients.\n15. Active or uncontrolled serious infection; A)known human immunodeficiency virus (HIV) infection; B) known history of clinically significant liver disease, including: viral hepatitis \\[known hepatitis B virus (HBV) carriers must exclude active HBV infection, namely HBV DNA positive (\\> 1104 copies \u002F mL or\\> 2000 IU \u002F mL); known hepatitis C virus infection (HCV) and HCV RNA positive (\\> 1103 copies \u002F mL)\\], or other hepatitis, cirrhosis;\n16. Any other disease, clinically significant metabolic abnormalities abnormal physical examination or laboratory abnormalities, according to the investigator, there is reason to suspect a disease or state is not suitable for the study drug (such as seizures and need treatment), or will affect the interpretation of the results, or make the patient in a high risk situation.\n17. Routine urine indicates urine protein 2 +, and 24-hour urine protein quantification\\> 1.0g.",{"count":263,"type":23},72,[265],"PHASE2","This is a prospective, multi-center, randomized controlled clinical intervention study, aiming to explore the effectiveness and safety of mfolfox6 and hlx04 regimens combined with slulimumab as first-line treatment for MSS-type initial unresectable metastatic colorectal cancer after induction therapy. This study plans to include a total of 72 patients with untreated MSS-type initial unresectable metastatic colorectal cancer.\n\nThis study randomly allocated groups through a randomization system, and entered the following treatment groups at a ratio of 1:1: (1) Experimental group: mfolfox6 and hlx04 regimen induction therapy followed by slulimab treatment (36 cases); (2) Control group Group: mfolfox6 and hlx04 regimen treatment (36 cases).",[30,31,268],"Colo-rectal Cancer","2024-06-30",{"date":271,"type":36},"2024-07-09",{"date":273,"type":23},"2024-07-01",{"date":275,"type":23},"2026-06-30",{"name":277,"class":68},"Sir Run Run Shaw Hospital",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":254},"100537917","lower-silesia-culotte-bifurcation-registry-lscbr-100537917","NCT06284057","Lower Silesia Culotte Bifurcation Registry (LSCBR).","Double Kissing (DK) vs Culotte Culotte. Lower Silesia Culotte Bifurcation Registry (LSCBR).","LSCBR","Inclusion Criteria:\n\n* Presence of significant changes in the coronary bifurcation requiring the implantation of two coronary stents using the Culotte or DK Culotte technique.\n\nExclusion Criteria:\n\n* Patients who underwent PCI with coronary stents prior to the index procedure for the bifurcation lesion studied.",{"count":53,"type":23},"The study aimed to evaluate the outcomes of bifurcation PCI using two techniques (Culotte vs. DK-Culotte) using data from a retrospective analysis.",[31,30],[290,291,292,293,294,295],"Percutaneous coronary intervention (PCI)","Bifurcation lesion","Culotte Technique","Double Kiss Culotte Technique","Acute Coronary Syndrome","Two-Stent Technique","2024-03-03",{"date":298,"type":36},"2024-03-06",{"date":300,"type":36},"2013-04-01",{"date":302,"type":23},"2028-04-01",{"name":253,"class":68},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":312,"targetDuration":236,"studyType":54,"phases":4,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":254},"100538233","lower-silesia-sinus-reducer-registry-100538233","NCT06288165","Lower Silesia Sinus Reducer Registry","Coronary Sinus Reducer Implantation for Refractory Angina - Long-Term Evaluation of Device Safety and Efficacy- Lower Silesia Sinus Reducer Registry (LSSRR)","LSSRR","Inclusion Criteria:\n\n1. present of chronic disabling refractory angina pectoris (Canadian Cardiovascular Society \\[CCS\\] classes 2-4) despite maximally tolerated anti-angina medical therapy\n2. Heart team evaluation with consideration of ineligibility for percutaneous or surgical revascularization procedures.\n\nExclusion Criteria:\n\n1. recent acute coronary syndrome (\\\u003C3 months),\n2. recent coronary revascularization (\\\u003C3 months)\n3. a mean right atrial pressure higher than 15 mm Hg\n4. coronary sinus proximal diameter \\\u003C10mm and \\>14mm\n5. life expectancy under 12 months,\n6. advanced heart failure (New York Heart Association \\[NYHA\\] Classification - classes 3-4),\n7. potential implantable cardiac resynchronization therapy defibrillator (CRT-D) implantation candidate.",{"count":313,"type":23},200,"Lower Silesia Sinus Reducer Registry is a , single-center, single-arm registry including patients with chronic disabling refractory angina pectoris (Canadian Cardiovascular Society \\[CCS\\] classes 2-4) despite maximally tolerated anti-angina medical therapy who underwent Coronary Sinus Reducer implantation .",[31,30],[317,318,319,320,321],"Coronary Sinus Reducer","Refractory angina","Chronic coronary artery diseases (CAD)","Non-obstructive Coronary artery diseases (CAD)","Coronary microvascular dysfunction","2024-02-24",{"date":324,"type":36},"2024-03-01",{"date":326,"type":36},"2022-05-11",{"date":328,"type":23},"2027-05-11",{"name":253,"class":68},{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":338,"enrollmentInfo":339,"targetDuration":236,"studyType":54,"phases":4,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":351,"leadSponsor":352,"locationsCount":254},"100509704","the-lower-silesia-shockwave-registry-100509704","NCT05916898","The Lower Silesia Shockwave Registry","Evaluation of the Safety and Efficiency of ShockWave Intravascular Lithotripsy (S-IVL) in Coronary Artery Diseases. The Lower Silesia Shockwave Registry (LSSR)","LSSR","Inclusion Criteria:\n\n* The presence of moderately to severely calcified lesions.\n* The presence of significant under-expansion (greater than 20% of the diameter) of the previously implanted stent.\n* Initial failure of the lesion preparation with either the NC balloon catheter or the atherectomy device.\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Target vessel dissection type 3 or higher according to spontaneous coronary artery dissection (SCAD) classification\n* Target vessel perforation due to previous unsuccessful lesion preparation\n* Pregnancy","99 Years",{"count":53,"type":23},"Lower Silesia Shockwave Registry (LSSR), is a observational registry collecting all consecutive cases of percutaneous coronary intervention (PCI) performed with the support of shockwave intravascular lithotripsy in two cooperating cardiac centers (Department of Cardiology, The Copper Health Centre, Lubin Poland, and Department of Cardiology, Provincial Specialized Hospital in Legnica, Poland).",[31,30],[240,241,343,344,242,345,346],"Shockwave intravascular lithotripsy","Stent under-expansion","lesion preparation","stent optimalization","2023-06-21",{"date":349,"type":36},"2023-06-23",{"date":249,"type":36},{"date":251,"type":23},{"name":253,"class":68},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":24,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":69},"100479000","dcb-versus-primary-selective-stenting-in-tasc-cd-femoropopliteal-artery-disease-100479000","NCT05517291","DCB Versus Primary Selective Stenting in TASC C\u002FD Femoropopliteal Artery Disease","Paclitaxel Coated Balloon Angioplasty Versus Primary Selective Stenting in the Treatment of TASC C\u002FD Chronic Femoropopliteal Artery Occlusive Disease: A Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Subject age 18-85yrs.\n* Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.\n* Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.\n* Rutherford category 2-5.\n* Subject has a de novo TASC C\u002FD femoropopliteal artery lesions which does not exceed to the segment P1 of popliteal artery.\n* The total length of target lesion ≤30cm.\n* Reference vessel diameter \\>4 mm and \\\u003C6.5 mm by visual assessment.\n* Patent inflow artery with stenosis \\\u003C30% and at least 1 infrapopliteal artery to the ankle (\\\u003C50% diameter stenosis).\n* A guidewire has successfully traversed the target treatment segment.\n\nExclusion Criteria:\n\n* Acute thrombus in the target vessels.\n* Vessel stenosis or occlusion due to Buerger's disease or autoimmune arteritis.\n* Subject received prior stents implantation with in-stent restenosis or occlusion.\n* Reintervention of the target lesion \\\u003C90 days before the study procedure.\n* Acquired thrombophilia or uncontrolled hypercoagulation states.\n* Life expectancy \\\u003C12 months.\n* Severe renal（SCr≥2.5 mg\u002Fdl）or hemodialysis dependence.\n* Pregnancy, suspected pregnancy, or breastfeeding during study period.\n* Contraindication to contrast media or any study-required medication (antiplatelet, anticoagulant, or thrombolytic agents, etc.).\n* Hypersensitivity to nitinol and\u002For paclitaxel.","85 Years",{"count":313,"type":23},[83],"This study aims to compare the mid- and long-term outcomes between paclitaxel-coated balloon and primary selective stenting in the treatment of TASC C\u002FD femoropopliteal artery occlusive disease.",[31,30],"2022-12-04",{"date":367,"type":36},"2022-12-06",{"date":369,"type":36},"2022-09-18",{"date":371,"type":23},"2027-12-31",{"name":373,"class":68},"Peking Union Medical College Hospital"]